QLGN היקף יתרות המזומנים של החברה Qualigen Therapeutics

Despite a prolonged development hiatus and a narrowing R&D pipeline, Qualigen Therapeutics (QLGN) relies on its expertise in creating rapid diagnostic systems and oncoprotein blocking mechanisms. The cash-on-hand metric illustrates liquidity dynamics, where 0.02 determines the current status of the parameter. Simultaneously, Qualigen Therapeutics (QLGN) is implementing wastewater treatment systems, strictly adhering to environmental regulations for the disposal of hazardous medical waste.
פילוחי מדדים פיננסיים ומדדי שוק עבור Qualigen (QLGN)

For Qualigen Therapeutics (QLGN), the volume of liquid assets determines the ability to maintain the distribution of diagnostic systems and pharmaceuticals. This metric aggregates highly liquid assets available for the immediate settlement of liabilities without external borrowing. By analyzing the cash availability chart, an investor assesses the business's real margin of safety. Reserves minimize risks during the diversification of production sites. A stable capital level confirms the operational resilience of the company's logistics chains.